• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.

作者信息

Prussick L, Rothstein B, Joshipura D, Saraiya A, Turkowski Y, Abdat R, Alomran A, Zancanaro P, Kachuk C, Dumont N, Gottlieb A B, Rosmarin D

机构信息

Department of Dermatology, Tufts Medical Center, Boston, MA, U.S.A.

Department of Diagnostic Imaging, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, Rhode Island, U.S.A.

出版信息

Br J Dermatol. 2019 Sep;181(3):609-611. doi: 10.1111/bjd.17822. Epub 2019 May 12.

DOI:10.1111/bjd.17822
PMID:30801662
Abstract
摘要

相似文献

1
Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa.一项开放标签、研究者发起的单中心探索性试验，评估抗白细胞介素-17A单克隆抗体司库奇尤单抗用于中度至重度化脓性汗腺炎患者的疗效。
Br J Dermatol. 2019 Sep;181(3):609-611. doi: 10.1111/bjd.17822. Epub 2019 May 12.
2
Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab.使用白细胞介素-17A抗体司库奇尤单抗成功治疗重度顽固性化脓性汗腺炎
Acta Derm Venereol. 2018 Jan 12;98(1):151-152. doi: 10.2340/00015555-2794.
3
A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.一项评估 Bermekimab 治疗化脓性汗腺炎患者的 II 期开放性研究显示其可改善炎症性皮损和疼痛
J Invest Dermatol. 2020 Aug;140(8):1538-1545.e2. doi: 10.1016/j.jid.2019.10.024. Epub 2020 Jan 29.
4
An evaluation of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa.评估司库奇尤单抗治疗中重度化脓性汗腺炎。
Expert Opin Biol Ther. 2024 Apr;24(4):225-232. doi: 10.1080/14712598.2024.2343112. Epub 2024 Apr 15.
5
Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report.严重化脓性汗腺炎经司库奇尤单抗治疗后缓解：一例报告。
Br J Dermatol. 2018 Jul;179(1):182-185. doi: 10.1111/bjd.15769. Epub 2018 Mar 25.
6
Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.抗TNF治疗失败后使用布罗达单抗成功治疗顽固性臀部化脓性汗腺炎。
Int J Dermatol. 2020 Jun;59(6):733-735. doi: 10.1111/ijd.14792. Epub 2020 Feb 3.
7
Anti-IL17 Secukinumab in hidradenitis suppurativa: A long-term drug survival analysis.抗白介素 17A 司库奇尤单抗治疗化脓性汗腺炎：长期药物生存分析。
Exp Dermatol. 2024 Jul;33(7):e15140. doi: 10.1111/exd.15140.
8
Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa.替拉珠单抗治疗中度至重度化脓性汗腺炎
Australas J Dermatol. 2020 Nov;61(4):e488-e490. doi: 10.1111/ajd.13377. Epub 2020 Jul 6.
9
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial.司库奇尤单抗治疗中度至重度化脓性汗腺炎：一项开放标签试验的结果
J Am Acad Dermatol. 2020 Jun;82(6):1524-1526. doi: 10.1016/j.jaad.2020.02.005. Epub 2020 Feb 7.
10
Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa.司库奇尤单抗可能是治疗化脓性汗腺炎继发系统性淀粉样变的方法。
Dermatol Ther. 2020 Nov;33(6):e14205. doi: 10.1111/dth.14205. Epub 2020 Sep 11.

引用本文的文献

1
Secukinumab Treatment in Patients with Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study.司库奇尤单抗在现实临床环境中治疗化脓性汗腺炎患者的多中心研究
Dermatol Pract Concept. 2025 Jan 30;15(1):4915. doi: 10.5826/dpc.1501a4915.
2
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa.白细胞介素-17抑制剂在化脓性汗腺炎治疗中的应用
BioDrugs. 2025 Jan;39(1):53-74. doi: 10.1007/s40259-024-00687-w. Epub 2024 Nov 28.
3
Hidradenitis Suppurativa: A Review of the Biologic and Small Molecule Immunomodulatory Treatments.
化脓性汗腺炎：生物制剂和小分子免疫调节治疗综述
J Cutan Med Surg. 2025 Jan-Feb;29(1):NP1-NP20. doi: 10.1177/12034754241300292. Epub 2024 Nov 27.
4
Hidradenitis suppurativa: a new therapeutic approach for an old disease.化脓性汗腺炎：一种针对古老疾病的新治疗方法。
Postepy Dermatol Alergol. 2024 Aug;41(4):350-356. doi: 10.5114/ada.2024.142185. Epub 2024 Aug 12.
5
Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study.司库奇尤单抗治疗中度至重度化脓性汗腺炎患者的机会窗和结局指标洞察：一项真实世界研究
Dermatol Ther (Heidelb). 2024 Jul;14(7):1875-1890. doi: 10.1007/s13555-024-01209-w. Epub 2024 Jun 19.
6
Data wobbles in hidradenitis suppurativa clinical trials and potential contributing factors: a retrospective review.化脓性汗腺炎临床试验中的数据波动及潜在影响因素：一项回顾性研究
Int J Womens Dermatol. 2024 Jun 7;10(2):e152. doi: 10.1097/JW9.0000000000000152. eCollection 2024 Jun.
7
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study.司库奇尤单抗用于阿达木单抗治疗失败的化脓性汗腺炎患者：一项52周的真实世界研究。
Clin Cosmet Investig Dermatol. 2024 Jan 23;17:159-166. doi: 10.2147/CCID.S449367. eCollection 2024.
8
Is Exploration of Alternate Immune Pathways Needed in Hidradenitis Suppurativa? A Case of Atopic Dermatitis and Concurrent Hidradenitis Suppurativa Responding to Dupilumab.化脓性汗腺炎是否需要探索其他免疫途径？1例特应性皮炎合并化脓性汗腺炎患者对度普利尤单抗治疗有效。
Case Rep Dermatol Med. 2023 Oct 23;2023:5189034. doi: 10.1155/2023/5189034. eCollection 2023.
9
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data.古塞库单抗、司库奇尤单抗和替拉珠单抗治疗化脓性汗腺炎：现有试验及真实世界数据综述
Clin Cosmet Investig Dermatol. 2023 Sep 18;16:2525-2536. doi: 10.2147/CCID.S418748. eCollection 2023.
10
Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies.化脓性汗腺炎的新兴治疗方法及临床试验概况 第一部分：局部和全身药物治疗
Dermatol Ther (Heidelb). 2023 Aug;13(8):1661-1697. doi: 10.1007/s13555-023-00956-6. Epub 2023 Jul 4.